CISCRP's Latest Perceptions & Insights Study
The study gathered responses from more than 12,000 people around the world--including 3,000 study volunteers--about their views and experiences with clinical research.
The Center for Information and Study on Clinical Research Participation (CISCRP) has released reports based on its 2015 Perceptions & Insights Study. That study gathered responses from more than 12,000 people around the world--including 3,000+ study volunteers--about their views and experiences with clinical research, and offers insights into general clinical research perceptions, enrollment drivers and barriers, and study volunteer experiences during and after clinical trial participation. The results also examine a variety of subgroup differences including by race & ethnicity, respondent age, severity of illness and by geographic area. The official reports are available on the CISCRP website.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
